Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03786107 · ClinicalTrials.gov registry record
HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib
A clinical trial, sponsored by Puma Biotechnology.
- Terminated
- Registry status
- 1,583
- Enrollment target
NCT03786107 is a clinical trial that was terminated before completion, run by Puma Biotechnology. The registered enrollment target is 1,583 participants.
The verdict
NCT03786107 was terminated before completion, sponsored by Puma Biotechnology.
- TERMINATED
- Registry status
- 1,583 participants
- Enrollment target
Study Summary
This is a multi-center, observational genomic screening protocol to identify participants whose tumors harbor somatic mutations in the ERBB2 (HER2) gene, as measured in circulating tumor DNA (ctDNA) . Participants with histologically confirmed, hormone receptor positive, HER-2 negative, metastatic breast cancer (MBC) or metastatic cervical cancer (MCC) are eligible for screening at 6 months intervals, or if disease progression is suspected/confirmed. Blood samples will be collected from eligible participants and ctDNA will be extracted and sequenced at a central laboratory, using a HER2-targeted next generation sequencing (NGS) test. A certified molecular test report will be issued from the central laboratory and provided to the investigators and the study sponsor. Participants who are identified with HER2 mutations by this screening protocol will subsequently have access to an appropriate neratinib treatment protocol, pending medical eligibility.
Interventions
- DIAGNOSTIC_TEST Almac HER-Seq Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,583 participants |
| Start Date | 2019-03-14 |
| Est. Completion | 2021-01-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03786107
The ClinicalTrials.gov registry entry for NCT03786107 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1,583 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Puma Biotechnology, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Almac HER-Seq Assay is the first listed.
NCT03786107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03786107 about?
NCT03786107 is a clinical study titled "HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib". This is a multi-center, observational genomic screening protocol to identify participants whose tumors harbor somatic mutations in the ERBB2 (HER2) gene, as measured in circulating tumor DNA (ctDNA) . Participants with histologically confirmed, hormone receptor positive, HER-2 negative, metastatic b...
What is the current status of trial NCT03786107?
This trial is currently terminated. The enrollment target is 1,583 participants. The study started on 2019-03-14. Estimated completion is 2021-01-21.
What interventions are being tested in trial NCT03786107?
The interventions under investigation include: Almac HER-Seq Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03786107?
This trial is sponsored by Puma Biotechnology, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.